Last edition
News about "UX111 gene therapy Ultragenyx"
Ultragenyx Gets US FDA Nod for First MPS IIIA Gene Therapy
US FDA has approved Ultragenyx's FAYUVI, first-ever gene therapy for Sanfilippo Syndrome Type A (MPS IIIA), the company's second gene therapy approval.
UX111 Gene Therapy Ultragenyx | 21/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members